1. Home
  2. PRME vs NEXN Comparison

PRME vs NEXN Comparison

Compare PRME & NEXN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Prime Medicine Inc.

PRME

Prime Medicine Inc.

SELL

Current Price

$4.23

Market Cap

526.0M

Sector

Health Care

ML Signal

SELL

Logo Nexxen International Ltd. American Depository Shares

NEXN

Nexxen International Ltd. American Depository Shares

SELL

Current Price

$10.25

Market Cap

520.5M

Sector

Technology

ML Signal

SELL

Company Overview

Basic Information
Metric
PRME
NEXN
Founded
2019
2007
Country
United States
Israel
Employees
N/A
N/A
Industry
Medicinal Chemicals and Botanical Products
Computer Software: Programming Data Processing
Sector
Health Care
Technology
Exchange
Nasdaq
Nasdaq
Market Cap
526.0M
520.5M
IPO Year
2022
2021

Fundamental Metrics

Financial Performance
Metric
PRME
NEXN
Price
$4.23
$10.25
Analyst Decision
Buy
Buy
Analyst Count
13
9
Target Price
$7.03
★ $14.54
AVG Volume (30 Days)
★ 5.5M
482.1K
Earning Date
11-12-2026
11-12-2026
Dividend Yield
N/A
N/A
EPS Growth
★ 18.18
N/A
EPS
N/A
★ N/A
Revenue
★ $4,632,000.00
N/A
Revenue This Year
$18.58
$9.39
Revenue Next Year
$23.34
$9.89
P/E Ratio
★ N/A
$9.64
Revenue Growth
★ 55.28
N/A
52 Week Low
$2.67
$5.60
52 Week High
$5.91
$11.30

Technical Indicators

Market Signals
Indicator
PRME
NEXN
Relative Strength Index (RSI) 51.32 67.53
Support Level $2.94 $8.34
Resistance Level $4.80 $10.58
Average True Range (ATR) 0.53 0.54
MACD -0.08 0.18
Stochastic Oscillator 22.25 79.76

Price Performance

Historical Comparison
PRME
NEXN

About PRME Prime Medicine Inc.

Prime Medicine Inc is a biotechnology company focused on developing a new class of genetic medicines designed to provide durable, and potentially curative, treatment options for patients with diseases driven by defined genetic alterations, acquired cellular dysfunction, or dysregulated gene expression. Its program, PM577 for Wilson Disease, is designed to initially correct the H1069Q mutation in the ATP7B gene and is supported by preclinical data showing targeted correction and restoration of copper homeostasis in animal models. In addition, PM647 is being developed for alpha-1 antitrypsin deficiency, or AATD, another liver targeted disease with substantial unmet need.

About NEXN Nexxen International Ltd. American Depository Shares

Nexxen International Ltd is a globalized and flexible advertising technology platform with deep expertise in data and TV that helps empower advertisers, agencies, digital publishers, broadcasters, and others. The Digital Advertising Ecosystem of the company includes demand-side platform (DSP), supply-side platform (SSP), ad server, and data management platform (DMP) and also delivers a flexible and unified technology stack with and exclusive data at its core. The company operates in America, APAC, EMEA, and Rest of America, with majority revenue from United States.

Share on Social Networks: